Literature DB >> 12500209

Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin.

Averell H Sherker, Madeleine Senosier, Delia Kermack.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12500209     DOI: 10.1053/jhep.2003.50037

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

Review 1.  Treatment of Chronic HCV Infection in Patients With Thalassemia.

Authors:  Halim Bou Daher; Ala I Sharara
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-01-29

2.  Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis.

Authors:  Qing-He Nie; Guo-Rong Duan; Xin-Dong Luo; Yu-Mei Xie; Hong Luo; Yong-Xing Zhou; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

3.  Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy.

Authors:  Seyed Vahid Tabatabaei; Seyed Moayed Alavian; Maryam Keshvari; Bita Behnava; Seyyed Mohammad Miri; Pegah Karimi Elizee; Farhad Zamani; Sedigheh Amini Kafiabad; Ahmad Gharehbaghian; Bashir Hajibeigy; Kamran Bagheri Lankarani
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

4.  Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?

Authors:  Kalliopi Zachou; Pinelopi Arvaniti; Nikolaos K Gatselis; Kalliopi Azariadis; Georgia Papadamou; Eirini Rigopoulou; George N Dalekos
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

Review 5.  Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.

Authors:  Ehsan Aminizadeh; Seyed Moayyed Alavian; Ali Akbari Sari; Nasser Ebrahimi Daryani; Bita Behnava
Journal:  Hepat Mon       Date:  2016-03-06       Impact factor: 0.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.